In a patient taking quetiapine (Seroquel) who develops breast enlargement, could this be due to medication‑induced hyperprolactinemia and how should it be evaluated and managed?

Seroquel and Breast Enlargement

Yes, quetiapine (Seroquel) can cause breast enlargement through medication-induced hyperprolactinemia, though it is less likely to do so compared to other antipsychotics like risperidone. The first step is to measure a serum prolactin level and evaluate for symptoms of hyperprolactinemia 1.

Understanding the Mechanism

Quetiapine causes hyperprolactinemia through dopamine D2 receptor antagonism in the pituitary, removing dopamine's normal inhibitory effect on prolactin secretion 1. However, quetiapine is considered a prolactin-sparing antipsychotic because it dissociates rapidly from D2 receptors 2. Among antipsychotics studied, hyperprolactinemia occurred in only 35% of patients on olanzapine (similar class to quetiapine) compared to 81% on risperidone 1.

The FDA label confirms that 3.6% of quetiapine-treated patients experienced clinically significant prolactin elevations versus 2.6% on placebo 3. Elevated prolactin can cause gynecomastia (breast enlargement) in males and breast enlargement with galactorrhea in females through direct effects on breast tissue 3.

Evaluation Algorithm

Step 1: Confirm the diagnosis

• Measure serum prolactin level (normal: <20 ng/mL in males, <25 ng/mL in females)
• Document timing: hyperprolactinemia typically develops over 3 days and takes 3 days to normalize after drug discontinuation 1
• Check for other symptoms: galactorrhea, sexual dysfunction, menstrual irregularities, decreased libido 1

Step 2: Rule out other causes if prolactin is elevated

• If the onset of hyperprolactinemia does NOT coincide with quetiapine initiation, obtain a pituitary MRI to exclude prolactinoma or hypothalamic mass 1
• Medication-induced hyperprolactinemia typically causes levels of 25-100 ng/mL, though quetiapine rarely exceeds 200 ng/mL 1

Step 3: Assess for long-term complications

• Evaluate for hypogonadal symptoms (low libido, erectile dysfunction in males; amenorrhea in females) 1
• Consider bone mineral density testing if hyperprolactinemia is persistent with reproductive dysfunction 1, 4

Management Strategy

The Endocrine Society Clinical Practice Guideline provides clear direction 1:

For asymptomatic patients with elevated prolactin:

• No treatment is necessary 1
• Continue monitoring for symptom development

For symptomatic patients, follow this hierarchy:

1. First-line: Stop quetiapine if clinically feasible 1

   • Consult with the prescribing psychiatrist before discontinuation 1
   • Prolactin levels should normalize within 3 days 1

2. Second-line: Switch to a prolactin-sparing antipsychotic 1

   • Aripiprazole is the preferred alternative (has dopamine agonist activity that actively lowers prolactin) 1
   • Other options: clozapine (though requires monitoring), or continue quetiapine at lower dose 2
   • Evidence shows switching to quetiapine from high-prolactin agents normalizes levels 5, but since the patient is already on quetiapine, switching TO aripiprazole is appropriate

3. Third-line: Adjunctive aripiprazole 6

   • Add aripiprazole 5-10 mg to existing quetiapine if switching is not feasible
   • High-quality evidence shows this reduces prolactin by 59-68 ng/mL in patients with levels >50 ng/mL 6
   • Recent case reports support using brexpiprazole (similar mechanism) if aripiprazole is not tolerated 7

4. Address hypogonadism if present:

   • If quetiapine cannot be stopped/switched AND patient has hypogonadal symptoms or low bone mass, consider estrogen or testosterone replacement 1

Critical Caveats

Avoid dopamine agonists (bromocriptine, cabergoline) in psychiatric patients unless absolutely necessary, as they may exacerbate psychosis 1. The Endocrine Society places high value on avoiding psychosis exacerbation over treating hyperprolactinemia 1.

Monitor for breast cancer risk: While tissue culture studies suggest one-third of breast cancers are prolactin-dependent, and long-standing hyperprolactinemia may increase breast cancer risk, the human evidence remains limited 3, 8. A recent meta-analysis found increased breast cancer risk with antipsychotics causing significant prolactin elevation (RR 1.59 for high-prolactin agents) 8.

In children/adolescents: Quetiapine caused prolactin elevations in 13.4% of males and 8.7% of females in pediatric trials, though sexual adverse effects did not correlate well with prolactin levels except for galactorrhea 9.

The key principle: breast enlargement from quetiapine is uncommon but real, and management prioritizes switching to aripiprazole over adding dopamine agonists in psychiatric patients 1, 6.